Results 321 to 330 of about 5,215,493 (360)

Metal-Based Nanomedicines for Inducing Programmed Cell Death to Enhance the Efficacy of Cancer Immunotherapy. [PDF]

Int J Nanomedicine
Cheng X, Park N, Lee Y.
europepmc   +1 more source

Precise Regulation of Membrane Proteins: From Physical Technology to Biomolecular Strategy

Advanced Science, EarlyView.
This review summarizes the emerging strategies for the precise regulation of membrane proteins using physical stimuli and biomolecule‐based tools. These methods provide new insights into cell regulation and offer promising directions for future disease treatment.
Xiu Zhao, Qingqing Zhou, Mengli Li, Wen Zou, Zhenzhong Zhang, Jinjin Shi, Junjie Liu   +6 more
wiley   +1 more source

Viral warriors: Unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy. [PDF]

Mol Ther Oncol
Ghavimi R, Rahimian L, Mohammadi M, Dutta O, Mohan H, Chouljenko V, Omolekan TO, Chamcheu JC, Kousoulas KG.   +8 more
europepmc   +1 more source

Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring

Advanced Science, EarlyView.
Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang, Xin Zhou, Min Liu, Meimei Huang, Peirong Chen, Xinying Li, Fangchao Xue, Wenyan Zhao, Di Liu, Lang Li, Yuangang Lu, Wen Zeng   +11 more
wiley   +1 more source

A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014-2024). [PDF]

Front Oncol
Yang Z, Yang L, Wang Y, Ren X, Cui Y, Li Y, Wu J.   +6 more
europepmc   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
wiley   +1 more source

Advances in Tumor Antigen Vaccines: A New Frontier in Cancer Immunotherapy. [PDF]

Int J Med Sci
Feng W, Zhao Y, Yu D, Jia W, Cao H, Zhang Y, Cao J, Li Z.   +7 more
europepmc   +1 more source

Targeting collagen to optimize cancer immunotherapy. [PDF]

Exp Hematol Oncol
Wang Y, Zhang F, Qian Z, Jiang Y, Wu D, Liu L, Ning X, Mei J, Chen D, Zhang Y.   +9 more
europepmc   +1 more source

Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy. [PDF]

Mol Cancer
Zhang H, Fan J, Kong D, Sun Y, Zhang Q, Xiang R, Lu S, Yang W, Feng L, Zhang H.   +9 more
europepmc   +1 more source

Cracking the code of cancer immunotherapy resistance: emerging roles of pyroptosis and necroptosis. [PDF]

J Exp Clin Cancer Res
Lei K, Chen J, Deng Y, Peng Y, Zhai X, Ren X, Zhao J, Chen B, Jiang C.   +8 more
europepmc   +1 more source